-The Times of India NEW DELHI: Cancer is thought to be the great leveler. Whether you are an Indian or a Korean or Icelander, cancer will bring death. But a massive study of 26 million cancer patients over 15 years has shown that survival rates in the 10 most prevalent types of cancer vary hugely across countries. Survival rates in India are quite low for most types of cancer, less than...
More »SEARCH RESULT
Total Matching Records found : 221
Half-full, half-empty -Subir Gokarn
-Business Standard India's mixed record on the Millennium Development Goals is a pointer to policy priorities In 2000, the United Nations held a Millennium Summit, at which the membership adopted the Millennium Development Goals (MDGs). Spanning a range of development indicators - poverty, gender, health, education and the environment - the MDGs essentially established a set of targets for the global community to achieve by 2015. The framework sets eight broad...
More »Diagnosis in ‘Digital India’ -Divvy K Upadhyay, Dean F Sittig and Hardeep Singh
-The Hindu The government must recognise the role low-cost health IT innovations could play in improving diagnostic accuracy, including many that would be useful for rural India The Diagnosis of the first patient with Ebola in the U.S. was initially missed in an emergency room late night on September 25. Thomas Duncan, a Liberian national visiting Dallas, Texas, complained of flu-like symptoms and fever, but after lab work and CT scans, was...
More »Access denied -Kundan Pandey
-Down to Earth Shortage of antiretroviral drugs and lack of Diagnosis is not new in India, but government does not admit to the crisis The fight against HIV/AIDS in India is becoming tougher by the day as patients continue to face an acute shortage of antiretroviral drugs. This is an alarming situation for a country with the third-highest number of HIV+ people in the world-2.1 million. In 2012, about 140,000 people in...
More »Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma
-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...
More »
